View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
March 26, 2013

NICE recommends two treatments for cystic fibrosis

The National Institute of Clinical Excellence (NICE) has recommended the approval of Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe for the treatment of lung infections in patients with cystic fibrosis.

By Nikitha Ladda

lungs

The National Institute of Clinical Excellence (NICE) has recommended the approval of Novartis‘ Tobi Podhaler and Forest Laboratories’ Colobreathe for the treatment of lung infections in patients with cystic fibrosis.

In its guidance published today, the UK health watchdog said Tobi Podhaler (tobramycin) is recommended as an option for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with cystic fibrosis, but only in certain circumstances.

NICE said the dry powder inhaler should be used in patients when nebulised Colobreathe is contraindicated, not tolerated or has not produced an adequate response.

Novartis must also offer the drug at a discounted rate as part of the patient access scheme under the National Health Service. The list price cost for 56 days of treatment is £1,790 excluding VAT.

Colobreathe (colistimethate sodium) is recommended as an option for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with cystic fibrosis, but only it if used for those patients who would clinically benefit from continued Colobreathe treatment, but do not tolerate it in its nebulised form.

Forest Lab should also provide Colobreathe with the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. The cost for 56 days of this treatment is £1,936 plus VAT before price cuts.

NICE Health Technology Evalation Centre director Professor Carole Longson commented on the guidance; "The primary cause of death in people with cystic fibrosis is respiratory failure resulting from chronic pulmonary infection caused by Pseudomonas aeruginosa. We are pleased to recommend both colistimethate sodium and tobramycin dry powders for inhalation as options for treating such infections in people with cystic fibrosis."

Cystic fibrosis is one of the UK’s most common life-threatening inherited diseases, and currently affects around 8,000 people.


Image: NICE has recommended the approval of Novartis’ and Forest Lab’s dry powder inhalers for the treatment of lung infections in patients with cystic fibrosis. Photo: Courtesy of FreeDigitalPhotos.net.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology